Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-04-28 | Ms. Mary K. MorelandExec. VP of HR | 5,31k | 501,69k | Acquisition Under Employee Benefit Plan | 94,41 | 121,45k | 4,58% |
| 2026-04-27 | Mr. Daniel J. StarksIndependent Director | 10,00k | 926,54k | Kauf | 92,65 | 6,73M | 0,15% |
| 2026-04-23 | Mr. Philip P. BoudreauCFO & Exec. VP of Finance | 2,20k | 201,30k | Kauf | 91,50 | 82,65k | 2,73% |
| 2026-04-23 | Mr. Philip P. BoudreauCFO & Exec. VP of Finance | 8,91k | 819,98k | Acquisition Under Employee Benefit Plan | 92,04 | 82,65k | 12,08% |
| 2026-03-02 | Mr. Eric ShroffSVP of Rapid & Molecular Diagnostics | -709,00 | 81,95k | Verkauf | 115,58 | 39,16k | -1,78% |
| 2026-02-27 | Mr. Eric ShroffSVP of Rapid & Molecular Diagnostics | -1,38k | 160,90k | Sale to Issuer | 116,26 | 39,16k | -3,41% |
| 2026-02-27 | Mr. Christopher J. ScogginsExec. VP of Diabetes Care | -5,00k | 580,95k | Sale to Issuer | 116,26 | 77,13k | -6,08% |
| 2026-03-02 | Mr. Daniel Gesua Sive SalvadoriExec. VP and Group President of Established Pharmaceuticals & Nutritional Products | -885,00 | 102,29k | Verkauf | 115,58 | 146,38k | -0,60% |
| 2026-02-27 | Mr. Daniel Gesua Sive SalvadoriExec. VP and Group President of Established Pharmaceuticals & Nutritional Products | -6,62k | 769,06k | Sale to Issuer | 116,26 | 146,38k | -4,32% |
| 2026-03-02 | Mr. Louis H. MorroneExec. VP of Core Diagnostics | -1,14k | 132,22k | Verkauf | 115,58 | 76,86k | -1,47% |
| 2026-02-27 | Mr. Louis H. MorroneExec. VP of Core Diagnostics | -4,04k | 469,69k | Sale to Issuer | 116,26 | 76,86k | -4,99% |
| 2026-03-02 | Ms. Mary K. MorelandExec. VP of HR | -613,00 | 70,85k | Verkauf | 115,58 | 116,14k | -0,53% |
| 2026-02-27 | Ms. Mary K. MorelandExec. VP of HR | -4,63k | 538,28k | Sale to Issuer | 116,26 | 116,14k | -3,83% |
| 2026-03-02 | Mr. John A. McCoyVP of Finance & Controller | -585,00 | 67,61k | Verkauf | 115,58 | 24,69k | -2,31% |
| 2026-02-27 | Mr. John A. McCoyVP of Finance & Controller | -1,14k | 132,77k | Sale to Issuer | 116,26 | 24,69k | -4,42% |
| 2026-02-27 | Mr. Robert B. FordChairman, President & CEO | -30,31k | 3,52M | Sale to Issuer | 116,26 | 522,66k | -5,48% |
| 2026-02-27 | Ms. Lisa D. EarnhardtExec. VP & Group President of Medical Devices | -8,58k | 997,16k | Sale to Issuer | 116,26 | 90,41k | -8,67% |
| 2026-03-02 | Ms. Elizabeth CushmanExec. VP, General Counsel & Secretary | -263,00 | 30,40k | Verkauf | 115,58 | 38,57k | -0,68% |
| 2026-02-27 | Ms. Elizabeth CushmanExec. VP, General Counsel & Secretary | -1,42k | 165,21k | Sale to Issuer | 116,26 | 38,57k | -3,55% |
| 2026-02-27 | Mr. Philip P. BoudreauCFO & Exec. VP of Finance | -7,44k | 865,09k | Sale to Issuer | 116,26 | 71,54k | -9,42% |
| 2026-02-04 | Mr. Daniel J. StarksIndependent Director | 10,00k | 1,09M | Kauf | 108,33 - 109,14 | 6,72M | 0,15% |
| 2026-01-23 | Mr. Robert B. FordChairman, President & CEO | 18,80k | 2,01M | Kauf | 107,13 | 469,51k | 4,17% |
| 2025-12-11 | Mr. Daniel Gesua Sive SalvadoriExec. VP and Group President of Established Pharmaceuticals & Nutritional Products | -1,54k | 189,36k | Other Disposition | 123,28 | 132,23k | -1,15% |
| 2025-11-25 | Mr. Eric ShroffSVP of Rapid & Molecular Diagnostics | -1,59k | 203,04k | Verkauf | 128,02 | 30,38k | -4,96% |
| 2025-09-01 | Mr. John A. McCoyVP of Finance & Controller | -79,00 | 10,48k | Sale to Issuer | 132,66 | 21,04k | -0,37% |
| 2025-09-01 | Mr. Philip P. BoudreauCFO & Exec. VP of Finance | -387,00 | 51,34k | Sale to Issuer | 132,66 | 50,98k | -0,75% |
| 2025-08-08 | Mr. Philip P. BoudreauCFO & Exec. VP of Finance | -5,55k | 746,76k | Verkauf | 134,55 | 51,36k | -9,75% |
| 2025-06-30 | Mr. Louis H. MorroneExec. VP of Core Diagnostics | -269,00 | 36,15k | Sale to Issuer | 134,38 | 66,62k | -0,40% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
